Dr. Viktor Nyíri earned his LL.M. from the George Washington University in 1996. He is a 1994 graduate of the Eötvös Loránd University Law School of Budapest, and pursued post-graduate studies at the Central European University. Between 1996 and 2005, he gained experience as a lawyer, focusing on company law and M&A transactions. Since 2005 he has worked exclusively as a private investor, completing several venture capital and real estate investments individually and through his holding company, the NV Asset Management Ltd. He has wide knowledge of the health care market and an extensive network of contacts. Due to his recent investments, Dr. Nyíri is recognized as one of the primary venture capital investors in the health sector.
Levente Zsembery earned his PhD in Financial Risk Management from the Budapest University of Economics in 2004, and his undergraduate degree in Finance in 1996 from the same institution. Since 1996, he has lectured at the University’s Institute of Finance. He also teaches courses in corporate finance, risk management and investment calculation at the Institute for Training and Consulting in Banking, at the Central European Training Centre for Brokers, and for MBA programs.
Dr. Zsembery served as consultant to the Ministry of Education, the Student Loan Center and later the Hungarian Development Bank (MFB), where he helped to develop and restructure the Hungarian student loan program. He advised the Budapest Stock Exchange in preparing for the unified European capital market regulation system, and served as a consultant to the Hungarian Financial Supervisory Authority (PSZÁF) in the Brau Union case.
In 2005-2006, Dr. Zsembery worked as Director of Capital Market Transactions for the Hungarian State Motorway Management Company. Between 2006 and 2010, he was Director of UniCredit CAIB Hungary, Hungary’s leading Hungarian investment bank. He was involved in significant transactions including privatization of the Hungarian airline Malév, sale of MÁV Cargo and BorsodChem subsidiaries, and the Richter Gedeon exchangeable bond issue. He has served as CEO of the Fund Management Company since 2010. Dr. Zsembery is an active member of the HVCA (Hungarian Venture Capital Association), serving as its Chairman since 2015.
István Bertóti-Dohovics earned his M.S. in Finance, with an emphasis in Company Valuation, from the Budapest University of Economics in 2001. As part of the Community of European Management Schools program, he studied at the Stockholm School of Economics (1999), followed by an internship at Morgan Stanley Dean Witter in London (2000). He obtained a CEMS Master in Management degree in 2003, and the Chartered Financial Analyst (CFA) qualification in 2008.
He began his professional career at the Strategy and Business Development Department of MOL Hungarian Oil and Gas Plc., where he was involved in divestiture of non-core affiliates between 2001 and 2003. From 2003, he worked for Raiffeisen Bank: six years in real estate project financing, leveraged buy-out and syndicated lending in various industries, followed by two years as manager of the bank’s medium- and large enterprise division. During the next four years, he headed the bank’s corporate division in the areas of pre-workout and early warning.
He joined X-Ventures in 2015 with the mandate of maximizing the value of his assigned portfolio, representing the ownership interests of the fund, analyzing new investment possibilities, submitting them to the decision making body, and managing the execution of those approved by the Investment Committee.
Laszlo Bicskei received an M.Sc. in Biomedical Engineering and an M.Sc. in Computer Sciences with a specialisation in Artificial Intelligence from the Budapest University of Technology and Economics in 2009. He continued his studies at the Institute of Experimental Medicine of the Hungarian Academy of Sciences, followed by a 4-years-long postgradual research project in Computational Neuroscience at University College London.
Early in his career he developed biomedical algorithms that improve patient care at Innomed Medical Inc. and General Electric. Later he worked as a life sciences management consultant at Deallus Consulting in London. As a project manager he led numerous local and global engagements across multiple therapy areas and provided in-depth commercial and technological analysis, due diligence, market opportunity assessment and brand planning.
He joined X-Ventures in 2016 with the mandate of maximizing the value of the fund’s life sciences portfolio, representing the ownership interests of the fund and analysing new investment opportunities.
In addition to his MBA, Gábor Bedőcs holds diplomas in the fields of IT, engineering management, and tax advisory services. Since 2004, he has been responsible for Viktor Nyíri’s portfolio, overseeing its management from due diligence through the exit phase. Among other projects, he has managed investments involving the following companies: Laboratórium Ltd., GenoID, Biropharma, Omker, Naturland and Oxivit.
At the beginning of his career in the 1990s Viktor Déri managed investment service companies acting on the Hungarian funds market owned by banks (e.g. Budapest Bank, CIB, MFB). He partook in the development of the Hungarian capital market as president/member of several organisations related to the stock market.
Since the 2000s, he took part in the formation of the government-supported domestic venture capital market and as the President of Small Business Development Financial Ltd. and CEO of Corvinus Venture Fund Management Ltd. he managed numerous venture fund investments and exits.
In the first round of JEREMIE Programme he acted as investment director and member of the Investment Committee at Biggeorge’s-NV Venture Fund Management Ltd.
During his 12 years in the venture capital sector, Viktor has gained outstanding experience in the issues, possibilities and investor expectations towards Hungarian SMEs, as well as the ability of selecting the right projects and other unique features of venture fund management.
After earning a medical degree from the University of Szeged, Dr. Attila Erdős began work at the Institute of Pathology as a clinician. He completed his MBA at INSEAD in 1996. From 1996 to 1999, he headed the Baltic office of SmithKlineBeecham (currently GlaxoSmithKline) and later became the European Business Development Manager at the Disease Management Division. He worked as Zone Sales Manager for GE Medical Systems in charge of Southeast Europe from 1999 to 2005 and as Managing Director of GenoID Ltd. from 2005 to 2007. At present, he is responsible for coordinating the release of products and services of several biotechnological enterprises to the international market.
Anna Faludi completed her studies at the Budapest Business College, Faculty of International Management and Business. Between 2000 and 2005, she worked as a Secretary/Translator at a diplomatic mission in Budapest. She worked as an Office Manager since 2005 at the Biggeorge’s-NV Real Estate Ltd. She has been supporting the venture capital investments of the NV Group, and joined the team of X-Ventures in 2010. With effect from July 2017, Anna is responsible for the Back Office of X-Ventures Ltd.
Following his graduation from St. Stephen University, Gödöllő, as agricultural engineer and Hungarian-English translator, in 1992, he had worked over ten years in the financial and commodity futures markets. Then, following the turn of the millennium, he had begun his carrier in the private equity and venture capital industry and related businesses. From 2005 through 2010, he had worked as deputy CEO and later (2007-2010) as CEO and Member of the Board at Corvinus Venture Capital Fund Managing Ltd., where he was responsible for managing two venture capital funds, with a total of EUR 70 million in equity. In relation with these positions, he had also participated actively in establishing standard rules and regulations as well as regulated operations of venture capital fund management in Hungary.
Since 2010, he has been participating as Member of the Board in the financial and strategic management of a US based, venture capital backed drug-development group. In the meantime, he had also maintained his venture capital fund management activities as senior investment advisor in the teams of Finatech from 2012 to 2014 and X-Ventures from 2016 to 2016, respectively. In addition to that, he had been providing strategic business development consultancy to a clinical research and medical services group, also developing medical devices. In 2018, he rejoined the team of X-Ventures.
She started her carrier in the foreign trading industry, working for TESCO International Organization for Technical Scientific Cooperation and later for various privately owned import-export business. In addition to her advanced level education in foreign trade, she has graduated from Budapest Business Scool, as economist, majoring in Financial Institutions.
In 2004, she joined MFB Hungarian Development Bank Private Limited Company, as senior assistant in equity finance and asset management. Her main responsibilities included monitoring, reporting, customer relations and various other tasks related to the asset management of corporate holdings.
Representing MFB Bank in its Subsidiaries, between 2007 and 2010 she was designated as Member of the Board of Corvinus International Investment Private Limited Company as well as Member of the Executive Supervisory Board of Kisvállalkozás-fejlesztő Pénzügyi Zrt. where she had participated decision making in various equity investing and asset management activities of these companies. In 2018, she had joined X-Ventures Beta Plc.
After finishing his studies at the College of Finance and Accounting, Mr. Mester obtained a position at the Central European International Bank (today CIB Bank). Beginning in 1990, he worked in investment banking for CAIB Capital Market Advisors (and its predecessors). In 2005 he was named CEO. He brings wide experience in corporate advising, selling and acquiring companies. He participated in significant capital market transactions both in Hungary and internationally, such as the stock market listings of MOL and Matáv and the subsequent public offerings. In 2007, he served as Malév’s Deputy Director for infrastructure and portfolio management. From 2008 to 2010, he was Secretary of the National Ministry of Development and Economics in charge of competitiveness and international relations. At present, he manages international development projects for the French-owned Veolia company’s subsidiary in Hungary.
With a background in liberal arts and journalism, Mr. Nyíri joined GenoID Kft. in 2004, and was appointed the company’s Managing Director in 2007. During his term, the firm developed into one of the region’s most important laboratories for molecular diagnostics, research and forensic science.
Under Mr. Nyíri’s direction, the company achieved success in the privately funded health care market, took the lead in international R&D research consortia, had two patents accepted by the European Patent Office, and acquired unique know-how in the field of forensic genetics.
At present, Mr. Nyíri is a director of the biotech firm Neumann Diagnostics.
Attila Pechtol graduated in 2000 from the College of Finance and Accounting, with an emphasis on Financial Institutions. He performed analysis and controlling activities at several companies. Since 2004, he has worked as Director of Finance for the venture capital investments of Dr. Viktor Nyíri, with direct involvement in screening, preparing decisions, decision-making, monitoring and exit. Meanwhile, he obtained postgraduate certificates in Economics and Law from the Institute of Post-Graduate Legal Studies at the Eötvös Loránd University (2004), and in Corporate Management from the Corvinus University of Budapest (2009).
Zoltán Széles obtained a degree in economics from the Szent István University of Gödöllő in 1996. He gained professional and management experience at the Budapest Fund Management Company and the K&H Securities Fund Management Company. He also worked as Supervisory Commissioner for the Hungarian Financial Supervisory Authority (PSZÁF). Between 2004 and 2006, he was Director General of Biggeorge’s–NV Property Investment Fund Management Company. While working for his own company, Unisource Ltd., he was responsible for the preparation, management and monitoring of R&D tendering projects co-financed by the Hungarian State and the European Union.